124 related articles for article (PubMed ID: 12930393)
1. Effective graft-versus-leukaemia effect after allogeneic stem cell transplantation using reduced-intensity preparative regimens in Fanconi anaemia patients with myelodysplastic syndrome or acute myeloid leukaemia.
Guardiola P; Kurre P; Vlad A; Cayuela JM; Espérou H; Devergie A; Ribaud P; Socié G; Richard P; Traineau R; Storb R; Gluckman E
Br J Haematol; 2003 Sep; 122(5):806-9. PubMed ID: 12930393
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia.
Ayas M; Saber W; Davies SM; Harris RE; Hale GA; Socie G; LeRademacher J; Thakar M; Deeg HJ; Al-Seraihy A; Battiwalla M; Camitta BM; Olsson R; Bajwa RS; Bonfim CM; Pasquini R; Macmillan ML; George B; Copelan EA; Wirk B; Al Jefri A; Fasth AL; Guinan EC; Horn BN; Lewis VA; Slavin S; Stepensky P; Bierings M; Gale RP
J Clin Oncol; 2013 May; 31(13):1669-76. PubMed ID: 23547077
[TBL] [Abstract][Full Text] [Related]
3. Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia.
Mitchell R; Wagner JE; Hirsch B; DeFor TE; Zierhut H; MacMillan ML
Br J Haematol; 2014 Feb; 164(3):384-95. PubMed ID: 24172081
[TBL] [Abstract][Full Text] [Related]
4. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
5. Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
Davies JK; Hassan S; Sarker SJ; Besley C; Oakervee H; Smith M; Taussig D; Gribben JG; Cavenagh JD
Br J Haematol; 2018 Feb; 180(3):346-355. PubMed ID: 29076145
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
Pawson R; Potter MN; Theocharous P; Lawler M; Garg M; Yin JA; Rezvani K; Craddock C; Rassam S; Prentice HG
Br J Haematol; 2001 Dec; 115(3):622-9. PubMed ID: 11736947
[TBL] [Abstract][Full Text] [Related]
7. Follow-up by cytogenetic and fluorescence in situ hybridization analysis of allogeneic bone marrow transplantation in two children with Fanconi's anaemia in transformation.
Ortega M; Caballín MR; Ortega JJ; Olive T; Coll MD
Br J Haematol; 2000 Oct; 111(1):329-33. PubMed ID: 11091220
[TBL] [Abstract][Full Text] [Related]
8. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia.
Blaise D; Vey N; Faucher C; Mohty M
Haematologica; 2007 Apr; 92(4):533-41. PubMed ID: 17488664
[TBL] [Abstract][Full Text] [Related]
9. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
Alyea EP; Kim HT; Ho V; Cutler C; DeAngelo DJ; Stone R; Ritz J; Antin JH; Soiffer RJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1047-55. PubMed ID: 17067911
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens.
Parker JE; Shafi T; Pagliuca A; Mijovic A; Devereux S; Potter M; Prentice HG; Garg M; Yin JA; Byrne J; Russell NH; Mufti GJ
Br J Haematol; 2002 Oct; 119(1):144-54. PubMed ID: 12358919
[TBL] [Abstract][Full Text] [Related]
11. Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.
Malladi RK; Peniket AJ; Norton AE; Campbell AJ; Collins GP; Samol J; Eagleton H; Miller E; Morgenstern G; Jones J; Keen-Mcguire A; Barnardo M; Littlewood TJ
Eur J Haematol; 2004 Aug; 73(2):85-92. PubMed ID: 15245506
[TBL] [Abstract][Full Text] [Related]
12. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age.
Raiola AM; Van Lint MT; Lamparelli T; Gualandi F; Mordini N; Berisso G; Bregante S; Frassoni F; Sessarego M; Fugazza G; Di Stefano F; Pitto A; Bacigalupo A
Br J Haematol; 2000 Jun; 109(4):716-21. PubMed ID: 10929020
[TBL] [Abstract][Full Text] [Related]
13. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia.
Finke J; Nagler A
Leukemia; 2007 Jul; 21(7):1357-62. PubMed ID: 17508002
[TBL] [Abstract][Full Text] [Related]
16. Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab.
Matthews K; Lim Z; Pearce L; Pagliuca A; Alejandro Madrigal J; Mufti GJ; Barber LD
Br J Haematol; 2010 Jun; 149(6):879-89. PubMed ID: 20346011
[TBL] [Abstract][Full Text] [Related]
17. Second allogeneic stem cell transplantation in myeloid malignancies.
Hartwig M; Ocheni S; Asenova S; Wiedemann B; Zabelina T; Ayuk F; Kabisch H; Erttmann R; Kröger N; Zander AR; Bacher U
Acta Haematol; 2009; 122(4):185-92. PubMed ID: 19887774
[TBL] [Abstract][Full Text] [Related]
18. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis.
Flynn CM; Hirsch B; Defor T; Barker JN; Miller JS; Wagner JE; Blazar BR; Burns LJ; Macmillan ML; Arora M; Weisdorf D
Am J Hematol; 2007 Oct; 82(10):867-72. PubMed ID: 17616969
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need.
Shimoni A; Nagler A
Best Pract Res Clin Haematol; 2011 Sep; 24(3):369-79. PubMed ID: 21925090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
